Therapy Areas: Respiratory
Acceleron elects Robert K. Zeldin (MD) as CMO
6 July 2018 -

Biopharmaceutical company Acceleron Pharma Inc (NASDAQ:XLRN) revealed on Thursday the appointment of Robert K. Zeldin, MD as its chief medical officer. (CMO).

In the medical department, Dr Zeldin succeeds the company's outgoing CMO, Matthew Sherman, MD, who will continue until the anticipated mid-2018 release of topline Phase 3 data from the BELIEVE trial of luspatercept in beta-thalassemia patients and will then serve in an advisory capacity for one year thereafter.

Most recently, Dr Zeldin was a member of the Executive Committee as well as chief medical officer of Belgium-based Ablynx NV.

Previously, Dr Zeldin has served as senior vice president and head of Global Clinical Development at French pharmaceutical firm Stallergenes SA, vice president and US medical franchise head, Respiratory and Dermatology at Novartis Pharmaceuticals, as well as senior director, Clinical Development at Merck.

At the start of his career, Dr. Zeldin was employed as a medical officer at the US Food & Drug Administration's Center for Biologics Evaluation and Research, assessing efficacy and safety data from the clinical development of allergy-related therapies, vaccines and orphan products.

Login
Username:

Password: